Looking For A Top Momentum Pick? Why Procept BioRobotics Corp (NASDAQ: PRCT) Is A Great Choice

Procept BioRobotics Corp (NASDAQ:PRCT) price on current trading day, fall -1.16% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $79.34.

A look at the stock’s price movement, the close in the last trading session was $80.27, moving within a range at $76.67 and $82.6. The beta value (5-Year monthly) was 1.0. Turning to its 52-week performance, $85.81 and $24.83 were the 52-week high and 52-week low respectively. Overall, PRCT moved 23.20% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Procept BioRobotics Corp’s market cap currently stands at around $4.12 billion, with investors looking forward to this quarter’s earnings report slated for in September.

Analysts have a consensus estimate of 53.18M for the company’s revenue for the quarter, with a low and high estimate of 51.6M and 54.3M respectively. The average forecast suggests up to a 51.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 217.03M, representing a 59.40% jump on that reported in the last financial year.

Turning to the stock’s technical picture we see that short term indicators suggest on average that PRCT is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend PRCT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

PRCT’s current price about 23.58% and 23.38% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 68.46, while 7-day volatility ratio is 8.85% and 6.04% in the 30-day chart. Further, Procept BioRobotics Corp (PRCT) has a beta value of 1.00, and an average true range (ATR) of 4.34. Analysts have given the company’s stock an average 52-week price target of $75, forecast between a low of $49 and high of $79. Looking at the price targets, the low is 38.24% off current price level while to achieve the yearly target high, price needs to move 0.43%. Nonetheless, investors will most likely welcome a 5.47% jump to $75 which is the analysts’ median price.

If we refocus on Procept BioRobotics Corp (NASDAQ:PRCT), historical trading data shows that trading volumes averaged 0.96 over the past 10 days and 669.05K over the past 3 months. The company’s latest data on shares outstanding shows there are 50.77 million shares.

The 5.89% of Procept BioRobotics Corp’s shares are in the hands of company insiders while institutional holders own 84.75% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.23 million on 2024-07-31, giving us a short ratio of 9.57. The data shows that as of 2024-07-31 short interest in Procept BioRobotics Corp (PRCT) stood at 1383.0 of shares outstanding, with shares short rising to 5.04 million registered in 2024-06-28. Current price change has pushed the stock 89.31% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PRCT stock continues to rise going into the next quarter.

Most Popular